Roche/Spark Deal Clears FTC In A Sigh Of Relief For Pharma Dealmakers
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.
You may also be interested in...
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
First-time offerings by drug developers fell from 2018 when 67 launched, but IPO investors’ fortunes improved with a year-end rally providing a 45.1% return versus a 7.5% loss in the prior year.